Dermatan sulfate and heparan sulfate as a biomarker for mucopolysaccharidosis I

• Published in: Journal of inherited metabolic disease 2010-04, Vol.33 (2), p.141-150
• Main Authors: Tomatsu, Shunji, Montaño, Adriana M, Oguma, Toshihiro, Dung, Vu Chi, Oikawa, Hirotaka, de Carvalho, Talita Giacomet, Gutiérrez, María L, Yamaguchi, Seiji, Suzuki, Yasuyuki, Fukushi, Masaru, Sakura, Nobuo, Barrera, Luis, Kida, Kazuhiro, Kubota, Mitsuru, Orii, Tadao
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Biochemistry; Biological and medical sciences; Biomarkers - blood; Biomarkers - urine; Carbohydrates (enzymatic deficiencies). Glycogenosis; Child; Child, Preschool; Chromatography, Liquid; Dermatan Sulfate - blood; Dermatan Sulfate - urine; Enzyme-Linked Immunosorbent Assay; Errors of metabolism; Female; Heparitin Sulfate - blood; Heparitin Sulfate - urine; Human Genetics; Humans; Infant, Newborn; Internal Medicine; Male; Mass Screening - methods; Medical genetics; Medical sciences; Medicine; Medicine & Public Health; Metabolic Diseases; Mucopolysaccharidosis I - blood; Mucopolysaccharidosis I - diagnosis; Mucopolysaccharidosis I - urine; Neonatal Screening - methods; Original Article; Pediatrics; Tandem Mass Spectrometry; Young Adult
• ISSN: 0141-8955; 1573-2665
• DOI: 10.1007/s10545-009-9036-3

Mucopolysaccharidosis I (MPS I) is an autosomal recessive disorder caused by deficiency of α-L-iduronidase leading to accumulation of its catabolic substrates, dermatan sulfate (DS) and heparan sulfate (HS), in lysosomes. This results in progressive multiorgan dysfunction and death in early childhood. The recent success of enzyme replacement therapy (ERT) for MPS I highlights the need for biomarkers that reflect response to such therapy. To determine which biochemical markers are better, we determined serum and urine DS and HS levels by liquid chromatography tandem mass spectrometry in ERT-treated MPS I patients. The group included one Hurler, 11 Hurler/Scheie, and two Scheie patients. Seven patients were treated from week 1, whereas the other seven were treated from week 26. Serum and urine DS (ΔDi-4S/6S) and HS (ΔDiHS-0S, ΔDiHS-NS) were measured at baseline, week 26, and week 72. Serum ΔDi-4S/6S, ΔDiHS-0S, and ΔDiHS-NS levels decreased by 72%, 56%, and 56%, respectively, from baseline at week 72. Urinary glycosaminoglycan level decreased by 61.2%, whereas urine ΔDi-4S/6S, ΔDiHS-0S, and ΔDiHS-NS decreased by 66.8%, 71.8%, and 71%, respectively. Regardless of age and clinical severity, all patients showed marked decrease of DS and HS in blood and urine samples. We also evaluated serum DS and HS from dried blood-spot samples of three MPS I newborn patients, showing marked elevation of DS and HS levels compared with those in control newborns. In conclusion, blood and urine levels of DS and HS provide an intrinsic monitoring and screening tool for MPS I patients.